James J. Rusthoven

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

Medicine, Oncology, Pharmacology +13

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B₁₂ as Front-Line Therapy in Malignant Pleural Mesothelioma

Giorgio V. Scagliotti, Dong-M. Shin, Hedy L. Kindler et al. · Journal of Clinical Oncology · 2003 · 255 citations

Medicine, Pharmacology, Pharmacotherapy +17

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2023 · 253 citations

Medicine, Oncology, Pharmacology +13

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Clet Niyikiza, Sharyn D. Baker, David E. Seitz et al. · PubMed · 2002 · 247 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

James J. Rusthoven, Elizabeth A. Eisenhauer, Charles Butts et al. · Journal of Clinical Oncology · 1999 · 218 citations

Medicine, Oncology, Pharmacology +14